The legalisation of medical cannabis in the UK in November 2018 marked a significant victory for patient advocates, particularly two mothers whose tireless campaigns highlighted the life-changing potential of these medicines for their children. However, nearly six years on, access to medical cannabis on the National Health Service (NHS) remains exceptionally rare, forcing the vast majority of patients to seek expensive private prescriptions.
The change in law followed high-profile cases, including that of Hannah Deacon, whose son Alfie Dingley suffered from a severe form of epilepsy. Alfie's condition led to numerous hospitalisations and a challenging quality of life for his family. Their public plea for access to cannabis oil, which they found significantly reduced his seizures, garnered widespread support and ultimately contributed to the government's decision to permit specialist doctors to prescribe cannabis-based medicines.
Despite this legislative shift, the reality for many UK patients is a postcode lottery of access and prohibitive costs. While specialist doctors can legally prescribe these medicines, the NHS has been slow to commission them, largely due to a lack of robust clinical trials specifically for NHS use and concerns over funding. This has created a two-tiered system where those who can afford private care are able to access treatment, while others are left without viable options.
The financial burden on families is substantial. Private prescriptions for medical cannabis can cost hundreds, if not thousands, of pounds per month, placing immense strain on household budgets. For conditions like severe epilepsy, where continuous treatment is required, these costs become unsustainable for many, undermining the spirit of the 2018 legalisation which aimed to provide relief to those in need.
Organisations representing patients and medical professionals have consistently called for clearer guidance from the National Institute for Health and Care Excellence (NICE) and greater education and training for NHS doctors. Without this, many GPs and consultants remain hesitant to prescribe, citing a lack of familiarity and support within the NHS framework. The Department of Health and Social Care has acknowledged the complexities but progress in integrating medical cannabis into mainstream NHS care has been slow.
The ongoing struggle for accessible medical cannabis highlights a broader challenge in healthcare innovation and commissioning within the NHS. While the legal framework exists, the practical implementation for patients remains a significant hurdle, perpetuating a system where only a privileged few can consistently benefit from these potentially life-altering treatments.